ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
Background: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) is an unmet need. ADS-5102 (amantadine) extended-release capsules is being developed for the treatment of LID in patients with PD. Objective: Evaluate the long-term safety and tolerability of 274 mg ADS-51...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2017-08-01
|
| Col·lecció: | Journal of Parkinson’s Disease |
| Accés en línia: | https://doi.org/10.3233/JPD-171134 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|